[HTML][HTML] Riociguat for the treatment of pulmonary arterial hypertension
…, N Galiè, F Grimminger, E Grünig… - … England Journal of …, 2013 - Mass Medical Soc
Background Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase
2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this …
2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this …
[HTML][HTML] Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension
…, G Simonneau, JL Vachiery, E Grünig… - … England Journal of …, 2015 - Mass Medical Soc
Background Data on the effect of initial combination therapy with ambrisentan and tadalafil
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension
…, H Wilkens, HA Katus, H Olschewski, E Grünig - Circulation, 2006 - Am Heart Assoc
Background— Pulmonary hypertension (PH) is associated with restricted physical capacity,
limited quality of life, and a poor prognosis because of right heart failure. The present study …
limited quality of life, and a poor prognosis because of right heart failure. The present study …
[HTML][HTML] Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension
Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-…
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-…
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
JG Coghlan, CP Denton, E Grünig… - Annals of the …, 2014 - ard.bmj.com
Objective Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death
in systemic sclerosis (SSc), facilitates earlier treatment. The objective of this study was to …
in systemic sclerosis (SSc), facilitates earlier treatment. The objective of this study was to …
[HTML][HTML] Risk stratification and medical therapy of pulmonary arterial hypertension
…, RN Channick, RP Frantz, E Grünig… - European …, 2019 - Eur Respiratory Soc
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability
over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and …
over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and …
ERS statement on chronic thromboembolic pulmonary hypertension
…, H Matsubara, T Ogo, E Grünig… - European …, 2021 - Eur Respiratory Soc
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute
pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries …
pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries …
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
…, D Pittrow, S Rosenkranz, E Grünig - European …, 2017 - Eur Respiratory Soc
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification
strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-…
strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-…
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study
…, MA Gómez-Sánchez, F Grimminger, E Grünig… - Circulation, 2013 - Am Heart Assoc
Background— By its inhibitory effect on platelet-derived growth factor signaling, imatinib
could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods …
could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods …
Frequency and phenotypes of familial dilated cardiomyopathy
E Grünig, JA Tasman, H Kücherer, W Franz… - Journal of the American …, 1998 - jacc.org
Objectives. This prospective study was performed to analyze the frequency and clinical
characteristics of idiopathic dilated cardiomyopathy (DCM). Background. Despite several …
characteristics of idiopathic dilated cardiomyopathy (DCM). Background. Despite several …